These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17954427)

  • 1. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States.
    Thurman JE
    Endocr Pract; 2007 Oct; 13(6):672-8. PubMed ID: 17954427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for diabetes: treatment with insulin pen devices.
    Cuddihy RM; Borgman SK
    Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
    Haak T; Edelman S; Walter C; Lecointre B; Spollett G
    Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin delivery by injection in children and adolescents with diabetes.
    Hanas R; de Beaufort C; Hoey H; Anderson B
    Pediatr Diabetes; 2011 Aug; 12(5):518-26. PubMed ID: 21481121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus.
    Peyrot M; Rubin RR
    Curr Med Res Opin; 2008 Aug; 24(8):2413-22. PubMed ID: 18627641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of insulin pen devices.
    McCoy EK; Wright BM
    Postgrad Med; 2010 May; 122(3):81-8. PubMed ID: 20463417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization.
    Davis EM; Christensen CM; Nystrom KK; Foral PA; Destache C
    Am J Health Syst Pharm; 2008 Jul; 65(14):1347-57. PubMed ID: 18593681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of insulin pen use in the United States and the United Kingdom.
    Da Costa S; Brackenridge B; Hicks D
    Diabetes Educ; 2002; 28(1):52-6, 59-60. PubMed ID: 11852744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin devices: addressing barriers to insulin therapy with the ideal pen.
    Spollett G
    Diabetes Educ; 2008; 34(6):957-60, 963, 967. PubMed ID: 19075079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing barriers to insulin therapy: the role of insulin pens.
    Magwire ML
    Am J Ther; 2011 Sep; 18(5):392-402. PubMed ID: 20838202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
    Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
    Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings.
    Aronson R; Gibney MA; Oza K; Bérubé J; Kassler-Taub K; Hirsch L
    Clin Ther; 2013 Jul; 35(7):923-933.e4. PubMed ID: 23790553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do different body colors and labels of insulin pens enhance a patient's ability to correctly identify pens for injecting long-acting versus short-acting insulins?
    Lefkowitz M
    J Diabetes Sci Technol; 2011 Jan; 5(1):136-49. PubMed ID: 21303636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient acceptance and reliability of new Humulin/Humalog 3.0 ml prefilled insulin pen in ten Croatian diabetes centres.
    Sucic M; Galic E; Cabrijan T; Ivandic A; Petrusic A; Wyatt J; Mincheva N; Milicevic Z; Malone J
    Med Sci Monit; 2002 Mar; 8(3):PI21-6. PubMed ID: 11884952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Review of Insulin Pens-Past, Present, and Look to the Future.
    Masierek M; Nabrdalik K; Janota O; Kwiendacz H; Macherski M; Gumprecht J
    Front Endocrinol (Lausanne); 2022; 13():827484. PubMed ID: 35355552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting use of insulin pens by patients with type 2 diabetes.
    Rubin RR; Peyrot M
    Diabetes Care; 2008 Mar; 31(3):430-2. PubMed ID: 18039802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes.
    Peyrot M; Rubin RR
    Diabetes Technol Ther; 2011 Jan; 13(1):43-8. PubMed ID: 21175270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens.
    Brunton S
    Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FlexPen: addressing issues of confidence and convenience in insulin delivery.
    Korytkowski M; Niskanen L; Asakura T
    Clin Ther; 2005; 27 Suppl B():S89-100. PubMed ID: 16519040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.